All In Biotech

Drug Trial Radar · NCT07252232

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

May 10, 2029

Study completion Jul 10, 2030

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Conditions

  • Pancreatic Cancer
  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
  • Resected Pancreatic Adenocarcinoma

Interventions

  • daraxonrasibDrug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) per InvestigatorTime frame: Up to approximately 5 years

Locations

86 sites in 10 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Lakewood, Colorado · Recruiting

  • Hartford Healthcare

    Hartford, Connecticut · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Mount Sinai Braman Comprehensive Cancer Center

    Miami Beach, Florida · Recruiting

  • Florida Cancer Specialists

    St. Petersburg, Florida · Recruiting

  • Piedmont Physicians Medical Oncology Atlanta

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • Community Health Network

    Indianapolis, Indiana · Recruiting

  • University of Kansas Medical Center Research Institute, Inc.

    Lawrence, Kansas · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute (DFCI)

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Cancer Center

    Rochester, Minnesota · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • University of Texas, Southwestern Medical Center

    Dallas, Texas · Recruiting

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.